Peptide therapy on TikTok: separating signal from hype

What did @erinamatomd actually say?

The video is a behind-the-scenes look at a Spravato (esketamine) treatment session at what appears to be a clinical setting. Dr. Amato describes Spravato as a "nasal esketamine spray" used to "fight depression," walks through a patient trainer device, and notes that nurses monitor treatments. The green dots on the trainer device indicate doses. The framing is promotional but grounded in a real, FDA-approved protocol.

No extraordinary claims are made here. There is no promise of a cure, no dosing advice directed at viewers, and no suggestion patients should seek this outside a supervised clinical setting. For a TikTok in the peptide-adjacent wellness space, that restraint is worth noting.

Does the science back this up?

Yes, substantially. Esketamine (the S-enantiomer of ketamine) received FDA approval in March 2019 under the brand name Spravato for treatment-resistant depression, and in August 2020 for major depressive disorder with acute suicidal ideation. The evidence base is real.

The pivotal trial published by Popova et al. (2019, JAMA Psychiatry) found that esketamine nasal spray plus a newly initiated oral antidepressant significantly reduced MADRS scores compared to placebo plus antidepressant in treatment-resistant patients. A separate trial by Ionescu et al. (2021, American Journal of Psychiatry) supported rapid symptom reduction in patients with active suicidal ideation. The drug works differently from traditional antidepressants, acting primarily as an NMDA receptor antagonist rather than targeting serotonin, which partly explains its faster onset, often within hours to days rather than weeks.

The monitoring requirement shown in the video is not optional theater. It is an FDA REMS (Risk Evaluation and Mitigation Strategy) requirement. Patients must be observed for at least two hours post-dose due to risks of dissociation, sedation, and blood pressure changes.

What did they get wrong (or right)?

The video calls it "escedamine" in the caption context, which appears to be a phonetic transcription artifact from the auto-transcript. The actual drug is esketamine. That is a transcription issue, not a clinical error by Dr. Amato.

One minor gap: the video does not mention that Spravato is a self-administered nasal spray used under direct clinical supervision, not a take-home medication. A viewer unfamiliar with the protocol might not understand that distinction. The trainer device demo is accurate, but the "why" behind supervised administration could have been explained more clearly.

What they got right is meaningful. The video accurately represents that patients use a training device before real treatment, that nurses monitor the session, and that this is a legitimate clinical procedure. Showing the trainer device specifically is a small but accurate detail, that device is a real component of the Spravato patient experience designed to standardize nasal spray technique.

What should you actually know?

Spravato is not a first-line antidepressant and it is not a replacement for therapy or standard antidepressants. It is approved specifically for treatment-resistant depression (failing at least two oral antidepressants) or MDD with acute suicidal ideation. It is expensive, often running $800 to $900 per session before insurance, and coverage is inconsistent.

The dissociative effects are real. In clinical trials, roughly 61 percent of patients experienced dissociation during sessions (Daly et al., 2018, JAMA Psychiatry). This is why the REMS program exists and why the video's emphasis on nurse monitoring is accurate, not just reassuring optics.

Response rates are promising but not universal. A meaningful subset of patients do not respond, and the durability of response is still being studied. If you are considering this treatment, the conversation should happen with a psychiatrist who can assess whether you meet the approved indications, not from a TikTok, however accurate it is.

Bottom line on this video

This is one of the more responsible depression-treatment videos you will find on TikTok. Dr. Amato shows a real clinical environment, describes a real FDA-approved treatment accurately, and does not oversell outcomes. The claim that Spravato is used to "fight depression" is appropriately modest language for a drug with a legitimate but specific approval. No red flags here, just a gap in explaining why the supervised setting is legally and medically required rather than optional clinical hospitality.